Changes in mitochondrial stability during the progression of the Barrett’s esophagus disease sequence by unknown
RESEARCH ARTICLE Open Access
Changes in mitochondrial stability during
the progression of the Barrett’s esophagus
disease sequence
N. J. O’Farrell1, R. Feighery1, S. L. Picardo1, N. Lynam-Lennon1, M. Biniecka2, S. A. McGarrigle1, J. J. Phelan1,
F. MacCarthy3, D. O’Toole3, E. J. Fox4, N. Ravi1, J. V. Reynolds1 and J. O’Sullivan1*
Abstract
Background: Barrett’s esophagus follows the classic step-wise progression of metaplasia-dysplasia-adenocarcinoma.
While Barrett’s esophagus is a leading known risk factor for esophageal adenocarcinoma, the pathogenesis of this
disease sequence is poorly understood. Mitochondria are highly susceptible to mutations due to high levels of reactive
oxygen species (ROS) coupled with low levels of DNA repair. The timing and levels of mitochondria instability and
dysfunction across the Barrett’s disease progression is under studied.
Methods: Using an in-vitro model representing the Barrett’s esophagus disease sequence of normal squamous
epithelium (HET1A), metaplasia (QH), dysplasia (Go), and esophageal adenocarcinoma (OE33), random mitochondrial
mutations, deletions and surrogate markers of mitochondrial function were assessed. In-vivo and ex-vivo tissues were
also assessed for instability profiles.
Results: Barrett’s metaplastic cells demonstrated increased levels of ROS (p < 0.005) and increased levels of random
mitochondrial mutations (p < 0.05) compared with all other stages of the Barrett’s disease sequence in-vitro.
Using patient in-vivo samples, Barrett’s metaplasia tissue demonstrated significantly increased levels of random
mitochondrial deletions (p = 0.043) compared with esophageal adenocarcinoma tissue, along with increased
expression of cytoglobin (CYGB) (p < 0.05), a gene linked to oxidative stress, compared with all other points across
the disease sequence. Using ex-vivo Barrett’s metaplastic and matched normal patient tissue explants, higher
levels of cytochrome c (p = 0.003), SMAC/Diablo (p = 0.008) and four inflammatory cytokines (all p values <0.05)
were secreted from Barrett’s metaplastic tissue compared with matched normal squamous epithelium.
Conclusions: We have demonstrated that increased mitochondrial instability and markers of cellular and mitochondrial
stress are early events in the Barrett’s disease sequence.
Keywords: Barrett’s esophagus, Mitochondrial instability, Oxidative stress
Background
Esophageal cancer is one of the most rapidly increasing
malignancies in the Western world [1]. Overall 5-year
survival rates are low at approximately 14 % [2]. The last
several decades have seen a change in the histological trend
of this malignancy with adenocarcinoma now representing
the leading sub-type in the West [3]. Barrett’s esophagus is
a pathologic precursor of esophageal adenocarcinoma.
Following the classic metaplasia-dysplasia-adenocarcinoma
sequence, it is speculated cancer development does not
occur directly from non-dysplastic disease [4]. While
Barrett’s esophagus follows this natural stepwise progres-
sion, the exact cellular instability mechanisms triggering
cancer conversion are not fully elucidated.
The rate of mutagenesis in mitochondrial DNA is
approximately 10-times higher than mutation rates in
nuclear DNA. This is due to a combination of factors
such as less proficient DNA repair mechanisms and high
levels of exposure to ROS generated by the mitochon-
dria themselves [5, 6]. The Warburg effect describes a
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phenomenon of altered energy metabolism in cancer cells,
with increased lactate production despite sufficient oxygen
to power oxidative phosphorylation [7]. This state of
aerobic glycolysis does not arise in normal functioning
cells and it is speculated that cancer cells divert from
normal energy pathways as a protective mechanism to
promote cell survival [8, 9]. These factors of increased
susceptibility to DNA injury, along with evidence of
altered energy metabolism in the cancer setting, have
highlighted the potential role of the mitochondria in
human cancer development [10–12].
To date, research has primarily focussed on clonal
mitochondrial mutations in relation to esophageal cancer
[13]. Little work has explored the role of random mito-
chondrial point mutations as a trigger for Barrett’s cancer
development. With each cell containing hundreds of mito-
chondria and correspondingly thousands of strands of the
mitochondrial genome, it is possible for wild type and mu-
tated mitochondrial DNA to co-exist [12]. It is hypothe-
sized that during tumor development cancer cells exhibit
a mutator phenotype, with higher frequencies of random
mutations, which are not supported by the normal rates
of mutagenesis seen in non-cancerous cells [14]. The
mutator phenotype hypothesis proposes that cancer cells
must incur increased rates of mutagenesis during disease
progression [14, 15], and as such, this theory suggests that
benign tumors with low levels of random mutations will
not progress to malignancy. Lee et al. [16] have demon-
strated significantly increased random mitochondrial mu-
tations in Barrett’s specialized intestinal metaplasia (SIM)
compared with adjacent normal tissue. It was hypothe-
sized that instability within the mitochondria play a crucial
role in Barrett’s cancer development, however, profiling
these changes along the Barrett’s disease sequence remain
largely unexplored.
With respect to Barrett’s esophagus, with less than
0.12 % of cases per year progressing to esophageal adeno-
carcinoma [17], it is prudent that we understand the early
instability mechanisms involved in the cancer switch. The
purpose of this study was to identify changes in mito-
chondrial mutation rates and function along the Barrett’s
disease sequence using in-vitro, in-vivo and ex-vivo models.
Methods
In-vitro cell line sequence
Four esophageal cell lines were used; HET1A, QH, Go
and OE33 cells representing the normal squamous
epithelium-SIM-high grade dysplasia (HGD)-esophageal
adenocarcinoma (EAC) sequence, respectively. HET1A
cells were obtained from American Type Culture Collec-
tion (ATCC) (LGC Standards, Middlesex, UK), and main-
tained in antibiotic-free bronchial epithelial cell basal media
(BEBM) enhanced with hormonal cocktail BEGM® Single-
Quots®. QH and Go cells were obtained from ATCC and
cultured in BEBM enhanced with BEGM® SingleQuots® and
supplemented with 10 % foetal calf serum (FCS) (Lonza,
MD, USA) and 1 % penicillin/streptomycin (Lonza). OE33
esophageal adenocarcinoma cells were sourced from the
European Collection of Cell Cultures (Sailsbury, UK) and
maintained in Roswell Park Memorial Institute (RPMI)
1640 medium (Lonza) supplemented with 10 % FCS and
1 % penicillin/streptomycin. All cell lines were maintained
at 37 °C.
Mitochondrial random mutation capture (RMC) assay in
cell lines and patient tissue
All research was carried out in accordance with the
Declaration of Helsinki, with all patients providing in-
formed written consent, and approval for this study
was granted by the St James’s Hospital and Adelaide,
Meath and National Children’s Hospital Institutional
Review Board. In vivo patient samples were snap frozen
in liquid nitrogen and stored at −80 °C for RMC assay ex-
periments. Patients with histologically confirmed SIM and
Barrett’s-associated EAC were recruited while in at-
tendance of Barrett’s esophagus surveillance endoscopy
or esophagectomy at the National Esophageal and Gastric
Centre at St. James’s Hospital, Dublin. In-vitro, HET1A,
QH, Go and OE33 cells, of similar cell passage number
were grown to 70–80 % confluence in 25 cm2 flasks to
isolate DNA for the RMC assay. In order to examine
mitochondrial instability, random mitochondrial point
mutations and deletions were quantified using detailed
methods previously published by our group [18]. This
RMC assay allows the quantification of point mutations
and deletions in the mitochondrial genome at single
molecule resolution. All tissues were analyzed in a
blinded fashion. All PCR products were sequenced by the
High-Throughput Sequencing Facility at the University of
Washington.
Evaluation of mitochondrial function using mitochondrial
assays for reactive oxygen species (ROS)
To further examine mitochondrial biology, ROS levels
were examined in vitro. Cells were seeded in 96 well
plates at density 2500 to 8000 cells/well, depending on
the cell line. Seeding at different concentrations was ne-
cessary to compensate for different growth rates between
different cell lines, in order to ensure the same degree of
confluence at the initiation of functional experiments.
Following 24 h, ROS levels were assessed. Cells were
incubated with 5 μM 2, 7-dichlorofluorescein diacetate
(Sigma-Aldrich) using our previously published proto-
cols [18]. Following 40 min incubation, the ROS probe
was removed, cells were analyzed using the Spectra Max
Gemini System at excitation 485 nm and emission 538 nm.
Mean fluorescence values for each cell line were obtained
from at least three independent experiments. Crystal violet
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assays were performed at the same time to allow for nor-
malization of ROS levels to cell number in each cell line.
Following 24 h, the media was decanted. Cells were washed
with PBS, fixed with 1 % gluteraldehyde (Sigma-Aldrich)
for 20 min, 1 % gluteraldehyde was discarded and 0.1 %
crystal violet solution was added for 30 min and removed
by washing with water. Plates were blotted on tissue paper
and allowed to air dry on the bench overnight. Once
dry, the cells were resuspended in 1 % Triton X100
(Sigma-Aldrich) and incubated on a shaker for 15 min.
The absorbance was read at 550 nm using a Perkin
Elmer Wallac 1420 Victor2 plate reader.
In-vivo Cytoglobin (CYGB), oxidative stress gene analysis
Cytoglobin (CYGB), a gene linked with oxidative stress
[19], was assessed in samples from patients representing
the Barrett’s disease sequence; normal squamous epi-
thelium (n = 6), SIM (n = 30), low-grade dysplasia (LGD)
(n = 6), HGD (n = 12) and EAC (n = 8). Expression of this
gene was used as a proxy marker for oxidative or cellular
stress, with increased ROS levels associated with an in-
crease in CYGB gene expression, in order to scavenge ex-
cess ROS [20–22]. The purpose of this experiment was to
allow us to perform an in-vivo cellular stress assessment
to complement our in-vitro ROS analysis. All cases were
prospectively recruited at our national referral centre.
Following each biopsy for standard histological examin-
ation, a matched biopsy for RNA extraction was imme-
diately taken directly adjacent. Matched biopsies were
placed in RNAlater preservative solution (Invitrogen)
and transferred to the laboratory. Normal control sam-
ples were taken from individuals attending for upper GI
endoscopy with no evidence of gastro-esophageal reflux
or other inflammatory aetiology. If the esophagus was
macroscopically normal at endoscopy, biopsies were
taken and stored as above. Only samples which demon-
strated normal squamous mucosa were used in further
analysis. Cancer samples were taken from individuals
undergoing assessment for a new diagnosis of EAC
arising in a setting of Barrett’s esophagus. All cancer
cases were chemotherapy and radiotherapy naïve. All
histological examination was carried out by GI patholo-
gists. All samples were placed immediately in RNAlater
at the time of endoscopy. Samples were transferred to a
4 °C fridge overnight. The following day all samples
were transferred to a −20 °C freezer for storage pending
the results of histological examination of matched tissues.
Following histological examination of matched biopsies,
samples were selected for analysis across the different
histological groups.
Patient material was homogenized using a Tissue-
Lyser for 5 mins at a frequency of 25 pulses per second
and RNA was extracted using the Qiagen Rneasy Mini
Kit (Qiagen). RNA quantity and quality was determined
spectrophotometrically using a Nanodrop 1000 spectro-
photometer (NanoDrop, Technologies, Wilmington, DE)
and quality assessment of all samples was performed on
the Agilent 2100 bioanalyzer platform (Agilent technolo-
gies, Santa Clara, CA), using the RNA Nano 6000 kit.
High quality total RNA was reverse transcribed to cDNA
using random hexamer oligodeoxyribonucleotides that
prime mRNA for cDNA synthesis. Quantitative PCR
was used to quantify cytoglobin mRNA expression (ABI
Biosystems) in samples relative to the 18S ribosomal
RNA endogenous control and analyzed using SDS 2.3
and SDS RQ Manager 1.2 relative quantification soft-
ware. Analysis of gene expression data was performed
using the 2ΔΔCt relative quantification method using the
change in the expression of a target gene relative to the
expression of a reference sample in the study.
Measurement of secreted mitochondrial proteins and
inflammatory cytokines from ex-vivo Barrett’s and
matched normal explant tissue
Barrett’s esophagus patients’ biopsies (n = 12), from areas
of SIM and surrounding normal tissue, were obtained
for fresh ex-vivo explant culture at 37 °C. Matched-
normal tissue biopsies were taken ≥ 5 cm from the most
proximal border of macroscopic Barrett’s. Biopsies were
immediately placed on saline-soaked gauze and trans-
ported within 10 min to the laboratory for ex-vivo cul-
ture 24-well plates containing 1 mL of M199 media
(Lonza) supplemented with 10 % FCS, 1 % penicillin/
streptomycin and 1 μg/ml insulin. Tissues were cultured
for 24 h, and conditioned media stored at −80 °C. Barrett’s
tissue was characterized by examining for the expression
of the columnar epithelium molecular markers cytoker-
atin 8 and villin (Metabion). Tissue viability following
explant culture was confirmed using a lactate dehydro-
genase (LDH) assay (Caymanchem, Michigan, USA).
Secretions of surrogate mitochondrial proteins, cyto-
chrome c and SMAC/Diablo were measured in explant
conditioned media using commercially available enzyme-
linked immunosorbent assay (ELISA) kits (R&D Systems)
using protocols as per manufactures’ instructions. The
levels of cytokines interleukin-8 (IL-8), interleukin-6
(IL-6), interleukin-1β (IL-1β) and tumour necrosis factor-α
(TNF-α) were measured using a multiplex assay from
Mesoscale Discovery® (Gaithersburg, MD, USA) using pro-
tocols as per manufactures’ instructions.
Statistical analysis
Data were analyzed with SPSS (PASW [Predictive Analytics
Software] version 18) (IBM, Armonk, New York, USA)
and Graph Pad Prism (Graph Pad Prism, San Diego, CA)
software. Differences between HET1A, QH, Go and
OE33 cell lines were calculated using unpaired Stu-
dent’s t-tests and Kruskal Wallis tests. In-vitro results
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were reported as mean and variation was expressed as
standard deviation (SD). In-vivo and ex-vivo: differ-
ences between continuous variables, for matched pa-
tient groups were calculated using Wilcoxon signed-
rank tests, while in unmatched patient groups the
Mann–Whitney U test was used. Patient data were re-
ported as mean and variation was expressed as standard
error of the mean (SEM = SD divided by the square
root of the sample size). Statistical significance was de-
fined as p ≤ 0.05.
Results
Mitochondrial instability levels in the Barrett’s disease model
In-vitro cell line assessment
Significantly elevated random mitochondrial point mu-
tations were an early event in the Barrett’s in-vitro
model (Fig. 1). Levels of random mitochondrial point
mutations were significantly increased in the QH,
metaplastic cells, compared to the HET1A cells (p =
0.024), Go cells (p = 0.008) and OE33 cells (p = 0.006).
No significant difference was demonstrated in the fre-
quency of random mitochondrial mutations between
the HET1A, Go and OE33 cell lines (all p values >0.05).
Levels of mitochondrial deletions were not evident in-
vitro.
In-vivo patient tissue assessment
While there were no differences in the frequency of
random mutations between SIM (mean = 8.269 × 10−5,
SEM = 2.223 × 10−5) and HGD/EAC tissue (mean =
7.422 × 10−5, SEM = 1.615 × 10−5) (p = 1.00) (data not
shown), interestingly, random mitochondrial deletions
were significantly increased in SIM tissue (mean = 1.322
x 10-5 SEM= 5.400 x 10−6) compared with HGD/EAC
(mean = 2.63 x 10−6, SEM= 1.250 × 10−6) (p = 0.043) (Fig. 2).
Random deletions were significantly increased in SIM
matched-normal tissue (mean = 2.983 × 10−5, SEM=
1.178 × 10−5) compared with SIM biopsies (p = 0.031)
(Fig. 2). While not significant, there was a trend towards in-
creased mitochondrial deletions in matched-normal tissue
(mean = 1.652 × 10−5, SEM= 2.331 × 10−6) compared with
HGD/EAC cancerous tissue (p = 0.063).
In-vitro Reactive Oxygen Species (ROS) assessment
There was a 4.2-fold increase in ROS in the QH cells
(mean 449.77, SD 26.848) (p < 0.0001), a 3.2-fold increase
in the Go cells (mean 346.4, SD 48.262) (p < 0.0001) and a
2.6-fold increase in the OE33 cells (mean 276.826, SD
23.188) (p < 0.0001), relative to the HET1As (mean
108.239, SD14.875). ROS levels were significantly higher
in the QH cells compared with all other points in the
Barrett’s cell line progression model (Fig. 3).
Fig. 1 Random mitochondrial point mutations in-vitro. There was a significantly increased frequency of random mitochondrial DNA mutations in
the QH cells (mean 7.710 × 10−5, SD 2.770 × 10−5) (n = 5) compared to HET1A (mean 2.560 × 10−5, SD 1.015 × 10−5) (n = 3), Go (mean 2.730 × 10−5,
SD 2.440 × 10−5) (n = 5) and OE33 (mean 2.500 × 10−5, SD 1.430 × 10−5) (n = 5) cells. This demonstrated that random mutations were an early
event in this in-vitro model of Barrett’s progression. *p ≤ 0.05
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Cytoglobin (CYGB) gene expression levels across the
Barrett’s disease progression model
There was a 25.9-fold increase in CYGB expression in
SIM (mean 11.013, SEM 8.493) compared with normal
biopsies (mean 0.425, SEM 0.231) (p = 0.013). Levels of
CYGB was significantly increased in SIM cases com-
pared to LGD (mean 6.03, SEM 1.555) (p = 0.010) and
EAC (mean 4.581, SEM 0.991) (p = 0.022) (Fig. 4).
Ex-vivo secretions of mitochondrial proteins and
inflammatory cytokines from Barrett’s and matched
normal explants
Secreted cytochrome c and SMAC/Diablo were signifi-
cantly higher from SIM tissue compared with matched
normal tissue (p = 0.003, p = 0.008 respectively) (Fig. 5a, b).
Inflammatory cytokines were also significantly increased
in SIM tissue compared with matched normal tissue;
IL-1β (p = 0.007), IL-6 (p = 0.0005), IL-8 (p = 0.002) and
TNF-α (p = 0.034) (Fig. 5c-f).
Discussion
The role of mitochondrial instability in the progression
of Barrett’s esophagus is poorly understood. Metabolic
imbalances, such as reduced response to apoptosis and
increased glycolysis are all features of cancer cells, and
are tightly regulated by the mitochondria [11, 23, 24].
Mutagenesis is a catalyst for cancer development, but
to date, clonal gene mutations have been the main type
of mitochondrial mutations analyzed with respect to
esophageal carcinoma. The mitochondrial genome is
more vulnerable to random mutations due to high ROS
exposure and lower DNA repair mechanisms compared
with nuclear DNA [5, 25]. Here we examined alterations
in random mitochondrial point mutations/deletions and
other markers of mitochondrial instability in the Barrett’s
esophagus disease sequence using in-vitro, in-vivo and ex-
vivo models.
Fig. 2 Random mitochondrial point deletions in-vivo. Wilcoxon matched-paired signed rank tests demonstrated a significantly increased level of
deletions in the SIM matched normal tissue compared with SIM (p = 0.031) and a trend towards increased deletions in HGD/EAC-matched normal
tissue compared with areas of HGD/EAC (p = 0.063). Mann Whitney-U test demonstrated significantly increased frequencies of deletions in SIM
compared to HGD/EAC tissue (p=0.043). *p ≤ 0.05
Fig. 3 Mitochondrial function, ROS levels, across the Barrett’s disease
sequence (n = 5). ROS was significantly lowest in the HET1A cells and
highest in the QH cells. ROS levels were significantly increased in the
QH cells compared with Go (p = 0.003) and OE33 (p < 0.0001) cell lines.
ROS levels were 1.3 times higher in the Go cell line compared with the
OE33s (p = 0.020). *p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.0005
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Using an in-vitro cell line model, we demonstrated
random mitochondrial mutations were significantly ele-
vated in the metaplastic, QH, cells compared with all
other points along the Barrett’s disease sequence, repre-
sented by the different cell lines. During tumor develop-
ment, cancer cells are understood to exhibit a mutator
phenotype with increased rates of mutagenesis during
disease progression [14, 15, 26–28]. In this theory, be-
nign tumors with low levels of random defects will not
progress to malignancy, and the mutator frequency will
influence risk. In other studies, increased random mito-
chondrial mutations have been reported in SIM com-
pared with adjacent normal tissue [16]. In our study,
using the RMC assay, mitochondrial deletions, a form of
rearrangement of the mitochondrial genome and a rec-
ognized marker of mitochondrial instability [29], were
significantly increased in SIM compared with HGD/
EAC. An increased frequency of deletions in SIM com-
pared with HGD/EAC is mirrored in colorectal polyp/
cancer studies [30], both supporting the hypothesis that
random mutations/deletions may become redundant as
the disease progresses. It is recognized once malignant
cells become established, selection processes ensue, with
more aggressive mutations surviving and undergoing sub-
sequent replication, with clonal mutations/deletions and
not random ones overtaking the initial catalyst for cancer
development at this time in the disease sequence [15, 31].
In this study, surrounding normal tissue demonstrated in-
creased deletions compared with areas of SIM or HGD/
EAC, suggesting mitochondrial instability is not just con-
fined to the visible site of pathological tissue abnormality
in the esophagus with Barrett’s disease, but exerts a field
effect, which has been previously demonstrated in colo-
rectal tumors [30].
The changes in the mitochondrial environment across
the Barrett’s disease sequence were further measured
through assessment of proxy markers of cellular stress
in-vitro and in-vivo. We have shown in-vitro that levels
of ROS in the QH, metaplasia cell line were significantly
elevated compared to other points along the Barrett’s
disease sequence. The esophagus is redox-sensitive [32],
but the role of oxidative stress across the Barrett’s
spectrum is largely unknown. Mitochondria are the main
source of ROS production, with excess levels of ROS
associated with oxidative damage [33–35]. The Warburg
effect theorizes cancer cells reprogram energy metabolism,
reducing oxidative phosphorylation and ROS production,
potentially decreasing injury to mitochondrial DNA
[36, 37]; perhaps this may explain the significant reduc-
tions in ROS in our in-vitro model between the QH
metaplastic cells and the Go and OE33 cells. The role
of ROS as a precursor for cancer progression has been
studied in many cancers. In breast cancer, BRCA-1, a
tumor suppressor gene, has been shown to play a role
in protecting against ROS damage; BRCA-1 mutations
have subsequently been implicated in loss of redox balance
with increased ROS, and may potentially drive cancer de-
velopment [38].
Studies have shown that the gene cytoglobin, CYGB, is
associated with ROS levels and induced in response to
oxidative stress where it can try to act to scavenge excess
ROS [20–22]. We have shown that CYGB was over-
expressed in SIM compared to levels detected in normal,
LGD and EAC tissue, supporting the concept that Barrett’s
metaplasia is an environment of oxidative stress, and the
pre-neoplastic tissue maybe more susceptible to oxidative
damage compared to neoplastic tissue similar to what has
been documented in the prostate [39]. Other studies have
shown that CYGB overexpression in-vitro can induce pro-
tection from chemically-induced oxidative stress but this
is only seen at non-physiological concentrations of cyto-
globin [19]. Loss of CYGB expression in the latter stages
of the disease potentially may reflect the inability to regu-
late oxidative stress, and loss of protection once tumor
growth is firmly established [19, 40].
As it is not possible to assess the active secretion of
mitochondrial and inflammatory proteins in fixed tissue,
using an ex-vivo explant model, we assessed the secre-
tion of mitochondrial proteins in metaplastic tissues, as
the greatest levels of instability and cellular stress were
observed at this pathological stage, and compared it to
matched normal mucosa. The explant model system is
superior to monolayer cell cultures as it encompasses
Fig. 4 Expression of CYGB along the Barrett’s disease sequence. The
expression of CYGB is demonstrated in normal (mean 0.425, standard
error of mean [SEM] 0.231), SIM (mean 11.013, SEM 8.493), LGD
(mean 6.03, SEM 1.555), HGD (mean 3.580, SEM 1.580) and EAC
biopsies (mean 4.581, SEM 0.991). SIM over-expressed CYGB relative
to LGD and EAC. There was a significant increase in CYGB in SIM,
LGD, HGD and EAC samples when compared with normal squamous
epithelium. *p < 0.05, **p < 0.005
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the tissue microenvironment [41]. Ex-vivo studies dem-
onstrated a significant increase in cytochrome c and
SMAC/Diablo, pro-apoptotic mitochondrial proteins in
SIM tissue compared with matched normal tissue, pat-
terns previously seen in esophageal cancer cell lines [42].
The mitochondria play a critical role in cell apoptosis.
Cytochrome c and SMAC/Diablo are apoptotic proteins,
released into the cytosol in order to activate a series of
caspases downstream. These findings suggest an increase
in mitochondrial biogenesis at the Barrett’s metaplastic
stage. Mitochondria have an important role in pro-
inflammatory signalling; similarly, pro-inflammatory me-
diators may also alter mitochondrial function. In parallel
with increases in mitochondria protein secretion from
metaplastic tissue, there were increases in inflammatory
cytokines, IL-1β, IL-6, IL-8 and TNF-α. This complements
previous observations from our group demonstrating as-
sociations between inflammation and mitochondrial in-
stability in another inflammatory condition [43]. These
data reinforce the finding that mitochondrial instability,
oxidative stress and inflammatory changes are early events
in the Barrett’s disease sequence. Strategies aimed at
targeting these processes may represent preventive and
therapeutic interventions.
Conclusions
We have shown that mitochondrial instability, oxidative
stress and increases in mitochondrial and inflammatory
protein production are activated early in the Barrett’s
disease progression sequence. Although unclear whether
mitochondrial dysfunction is the cause or consequence
of these events, this study shows that SIM occurs in an
environment of increased oxidative stress and mitochon-
drial instability.
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